A recent important case points to the discovery and development of Liraglutide, a peptide analogue derived from residue7–37 of glucagon-like peptide-1(GLP-1) used to treat type 2 diabetes (T2D) and obesity since 2009 [26]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.